#1 Clinical Trials Search in Europe

Ezetimibe

This article discusses a clinical trial that examined the pharmacokinetic interaction between ezetimibe (Ezetrol®) and atorvastatin (Lipitor®) in healthy volunteers. The study aimed to understand how these two cholesterol-lowering medications interact when taken together, providing valuable insights for their combined use in treating high cholesterol levels.

Table of Contents

What is Ezetimibe?

Ezetimibe is a medication used to lower cholesterol levels in the blood. It belongs to a class of drugs called cholesterol absorption inhibitors. Ezetimibe works differently from other cholesterol-lowering medications like statins, making it a valuable option for patients who cannot tolerate statins or need additional cholesterol reduction[1].

How Ezetimibe Works

Ezetimibe works by reducing the absorption of cholesterol in the small intestine. It specifically targets a protein called NPC1L1, which is responsible for cholesterol absorption. By blocking this protein, ezetimibe decreases the amount of cholesterol that enters the bloodstream from the digestive tract. This mechanism is different from statins, which work by reducing cholesterol production in the liver[1].

Medical Uses of Ezetimibe

Ezetimibe is primarily used to treat hypercholesterolemia, which is a condition characterized by high levels of cholesterol in the blood. It can be prescribed for the following purposes:

  • Lowering total cholesterol levels
  • Reducing low-density lipoprotein (LDL) cholesterol, also known as “bad” cholesterol
  • Decreasing the risk of cardiovascular events in patients with high cholesterol
  • As an alternative or additional treatment for patients who cannot tolerate statins or do not achieve adequate cholesterol reduction with statins alone[1]

Brand Names and Formulations

Ezetimibe is available under various brand names, including:

  • Zetia®
  • Ezetrol®
  • Acotral®

It is typically available as a 10 mg tablet for oral administration[2].

Dosage and Administration

The standard dose of ezetimibe is 10 mg once daily. It can be taken with or without food. Your doctor will determine the appropriate dosage based on your individual needs and medical condition[2].

Combination Therapy with Statins

Ezetimibe is often used in combination with statins, such as atorvastatin (Lipitor®), to achieve greater cholesterol reduction. The combination of ezetimibe and a statin can provide additional benefits in lowering LDL cholesterol compared to using either medication alone[3].

Pharmacokinetics of Ezetimibe

Pharmacokinetics refers to how a drug is processed by the body. For ezetimibe, key pharmacokinetic parameters include:

  • Absorption: Ezetimibe is rapidly absorbed after oral administration.
  • Distribution: It is extensively bound to plasma proteins.
  • Metabolism: Ezetimibe is primarily metabolized in the small intestine and liver to form an active metabolite.
  • Elimination: The drug and its metabolites are eliminated primarily through fecal excretion, with a smaller amount excreted in urine.
  • Half-life: The half-life (time it takes for half of the drug to be eliminated from the body) of ezetimibe is approximately 22 hours[3].

Potential Side Effects

While ezetimibe is generally well-tolerated, some patients may experience side effects. Common side effects may include:

  • Headache
  • Fatigue
  • Abdominal pain
  • Diarrhea
  • Joint pain

It’s important to discuss any side effects with your healthcare provider[1].

Drug Interactions

Ezetimibe may interact with other medications. Some notable interactions include:

  • Statins: When used in combination with statins, there may be an increased risk of muscle-related side effects.
  • Fibrates: Concurrent use with fibrates may increase the risk of gallstones.
  • Cyclosporine: Ezetimibe may increase cyclosporine levels in the blood.

Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions[3].

Aspect Details
Study Design Randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence, crossover study
Participants Healthy volunteers
Medications Studied Atorvastatin (Lipitor®) and Ezetimibe (Ezetrol®)
Dosages Atorvastatin 40mg, Ezetimibe 10mg
Treatment Duration 7 days per treatment period
Washout Period 11 days between treatment periods
Primary Outcomes AUCτ,ss and Cmax,ss of atorvastatin and free ezetimibe
Secondary Outcomes AUCinf,ss, Cavg,ss, %fluctuation, tmax,ss, t1/2, CL/Fss, Vd/Fss, and metabolic ratios
Study Aim To investigate pharmacokinetic drug interactions between atorvastatin and ezetimibe

FAQ

  • What was the purpose of this clinical trial? The purpose of this clinical trial was to investigate the pharmacokinetic drug interaction between atorvastatin (Lipitor®) and ezetimibe (Ezetrol®) after oral administration in healthy volunteers. This helps understand how these two medications interact in the body when taken together.
  • How was the study designed? The study was designed as a randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence, crossover study. This means participants received different combinations of the drugs in various sequences, allowing researchers to compare the effects of the medications alone and in combination.
  • What doses of medications were used in the study? The study used atorvastatin calcium 40mg (Lipitor® 40mg) and ezetimibe 10mg (Ezetrol® 10mg). These doses were administered either individually or in combination, depending on the study arm and phase.
  • How long did each treatment period last? Each treatment period lasted for 7 days, followed by an 11-day withdrawal period before the next treatment phase began. This allowed the researchers to observe the effects of the medications over time and ensure that previous treatments didn't interfere with subsequent ones.
  • What were the main outcomes measured in this study? The main outcomes measured were pharmacokinetic parameters such as AUCτ,ss (area under the curve at steady state), Cmax,ss (maximum concentration at steady state), and various other measures like AUCinf,ss, Cavg,ss, %fluctuation, tmax,ss, t1/2, CL/Fss, and Vd/Fss for both atorvastatin and ezetimibe. These parameters help understand how the drugs are absorbed, distributed, and eliminated in the body.

Ongoing Clinical Trials on Ezetimibe

  • Study on Lowering Cholesterol with Rosuvastatin or Rosuvastatin/Ezetimibe in Patients at High or Very High Risk of Cardiovascular Disease with High Cholesterol

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Croatia Germany Hungary Poland Slovenia

Glossary

  • Pharmacokinetics: The study of how drugs move through the body, including their absorption, distribution, metabolism, and excretion.
  • AUCτ,ss: Area Under the Curve at steady state, which represents the total drug exposure over time at equilibrium.
  • Cmax,ss: Maximum concentration of a drug in the blood at steady state, indicating the peak level of the drug.
  • Tmax,ss: Time to reach maximum concentration at steady state, showing how quickly the drug reaches its highest level in the blood.
  • T1/2: Half-life of a drug, which is the time it takes for the concentration of the drug in the body to be reduced by half.
  • CL/Fss: Apparent total body clearance of the drug from plasma at steady state, indicating how quickly the body eliminates the drug.
  • Vd/Fss: Apparent volume of distribution at steady state, representing how widely the drug is distributed in the body.
  • Ezetimibe: A cholesterol-lowering medication that works by reducing cholesterol absorption in the intestines.
  • Atorvastatin: A statin medication that lowers cholesterol by blocking an enzyme involved in cholesterol production in the liver.
  • Crossover study: A type of clinical trial where participants receive different treatments in a specific sequence, allowing comparison of effects within the same individual.

References

  1. https://clinicaltrials.gov/study/NCT00932620
  2. https://clinicaltrials.gov/study/NCT01597700
  3. https://clinicaltrials.gov/study/NCT02288338